Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Prashanth Kumar, Nisha Joseph, MD, Dhwani Almaula, MPH, Lawrence H Boise, PhD, Jonathan L. Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Sagar Lonial, MD FACP, Ajay K Nooka, MD MPH

Blood (2016) 128 (22): 4524.

https://doi.org/10.1182/blood.V128.22.4524.4524

Published: 2016

Journal Articles

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Ajay K Nooka, MD MPH, Nisha Joseph, MD, Larry H Boise, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Jonathan L. Kaufman, MD, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 492.

https://doi.org/10.1182/blood.V128.22.492.492

Published: 2016

Journal Articles

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Ajay K. Nooka, MD MPH, Jonathan L. Kaufman, MD, Madhusmita Behera, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Hannah Collins, ANP-BC, OCN, Vikas A. Gupta, MD PhD, Lawrence H Boise, PhD, Sagar Lonial, MD

Blood (2015) 126 (23): 5344.

https://doi.org/10.1182/blood.V126.23.5344.5344

Published: 2015

Journal Articles

Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Ajay K. Nooka, MD MPH, Jonathan L. Kaufman, MD, A. Tuba Karagulle Kendi, MD, Yan Li, Chikaodili O Obidike, Charise Gleason, MSN, ANP-BC, AOCNP, Lawrence H Boise, PhD, Sagar Lonial, MD

Blood (2015) 126 (23): 4202.

https://doi.org/10.1182/blood.V126.23.4202.4202

Published: 2015

Journal Articles

Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Charise Gleason, MSN, ANP-BC, AOCNP, Jonathan L. Kaufman, MD, Ajay K. Nooka, MD MPH, Kelly Valla, PharmD, BCOP, Leonard T Heffner, MD, Aditya Singh Bisht, Sanjay Manubolu, Melanie Watson, Lawrence H. Boise, PhD, Sagar Lonial, MD

Blood (2014) 124 (21): 5773.

https://doi.org/10.1182/blood.V124.21.5773.5773

Published: 2014

Journal Articles

Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea

Melanie Watson, RN, OCN, Ajay K. Nooka, MD MPH, Charise Gleason, MSN, ANP-BC, AOCNP, Kelly Valla, PharmD, BCOP, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2014) 124 (21): 5779.

https://doi.org/10.1182/blood.V124.21.5779.5779

Published: 2014

Journal Articles

Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma

Kelly Valla, PharmD, BCOP, Jonathan L. Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Lawrence H. Boise, PhD, Leonard T Heffner, MD, Sanjay Manubolu, Aditya Singh Bisht, Melanie Watson, Ajay K. Nooka, MD MPH, Sagar Lonial, MD

Blood (2014) 124 (21): 2139.

https://doi.org/10.1182/blood.V124.21.2139.2139

Published: 2014

Journal Articles

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Jonathan L. Kaufman, MD, Todd Zimmerman, MD, Cara A Rosenbaum, MD, Ajay K. Nooka, MD MPH, Leonard T Heffner, MD, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Colleen Lewis, MSN, ANP-BC, AOCNP, Cathy Sharp, RN, MN, OCN, Kenisha W Barron, B.S, CCRC, Sagar Lonial, MD

Blood (2014) 124 (21): 32.

https://doi.org/10.1182/blood.V124.21.32.32

Published: 2014

Journal Articles

Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients

Nishi N Shah, MBBS, Ajay K. Nooka, MD, MPH, Donald Harvey, Jonathan L. Kaufman, MD, Amelia Langston, MD, Dana Nickleach, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Leonard T Heffner, MD, Lawrence H. Boise, PhD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 5358.

https://doi.org/10.1182/blood.V122.21.5358.5358

Published: 2013

Journal Articles

Impact of Body Mass Index (BMI) On Overall Survival in Myeloma

Mukesh Kumar, MD, Ajay K. Nooka, MD, MPH, FACP, Amelia Langston, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Melanie Watson, Hannah Collins, ANP-BC, OCN, Daniela Casbourne, FNP-BC, AOCNP, Lawrence H. Boise, PhD, Jonathan L. Kaufman, MD, Edmund K. Waller, MD, PhD, Sagar Lonial, MD

Blood (2012) 120 (21): 4289.

https://doi.org/10.1182/blood.V120.21.4289.4289

Published: 2012

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Jonathan L. Kaufman, MD, Jatin J. Shah, M.D., Jacob P. Laubach, MD, Alaina R. Mitchell, BS, Cathy Sharp, R.N., Colleen Lewis, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Daniela Casbourne, FNP-BC, AOCNP, Ajay K. Nooka, MD, MPH, FACP, Leonard T Heffner, MD, Paul G. Richardson, MD, Robert Z. Orlowski, M.D., Ph.D., Sagar Lonial, MD

Blood (2012) 120 (21): 336.

https://doi.org/10.1182/blood.V120.21.336.336

Published: 2012

NARROW

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea

Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients

Impact of Body Mass Index (BMI) On Overall Survival in Myeloma

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only